Andersen Group (NYSE:ANDG) reported first-quarter 2026 revenue and adjusted EBITDA above its prior guidance, with management pointing to broad-based organic growth across tax service lines, higher revenue per professional and an active acquisition pipeline expected to contribute more meaningfully in
Astrana Health (NASDAQ:ASTH) CEO and President Brandon Sim said the value-based care company is seeing early benefits from its acquisition of Prospect, while reporting stronger-than-expected first-quarter trends across medical costs, free cash flow and revenue.
Speaking at a Bank of America healthc
a.k.a. Brands (NYSE:AKA) reported a stronger-than-expected start to fiscal 2026, with first-quarter net sales rising 3% to $132.5 million and Adjusted EBITDA increasing to $5.1 million, management said on the company’s earnings call.
Chief Executive Officer Ciaran Long said the results reflected “s
Upexi (NASDAQ:UPXI) reported higher fiscal third-quarter revenue but a large net loss tied primarily to unrealized losses on its Solana holdings, as management said a weak crypto market weighed on both token prices and industry valuation multiples during the quarter ended March 31, 2026.
Chief Exec
Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
President and Chief Executive Officer Jayson Rieger sai
Luxury cruise operator Viking (NYSE:VIK) will be announcing earnings results this Thursday morning. Here’s what to expect. Viking beat analysts’ revenue expe...
Semiconductor quality control company Nova (NASDAQ:NVMI) will be reporting earnings this Thursday before market open. Here’s what you need to know. Nova beat...
Video sharing platform Rumble (NASDAQGM:RUM) will be reporting earnings this Thursday afternoon. Here’s what to look for. Rumble met analysts’ revenue expect...
Outdoor lifestyle products brand (NYSE:YETI) will be reporting results this Thursday morning. Here’s what investors should know. YETI met analysts’ revenue e...
Digital banking platform Nubank (NYSE:NU) will be reporting results this Thursday after market hours. Here’s what investors should know. Nubank beat analysts...
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
President and Chief Executive Officer M
OptimizeRx (NASDAQ:OPRX) reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics
Paysign (NASDAQ:PAYS) reported what executives described as the strongest start to a year in the company’s history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contribu
QuickLogic (NASDAQ:QUIK) reported higher first-quarter fiscal 2026 revenue and reiterated expectations for strong full-year growth, as management highlighted progress in radiation-hardened FPGA products, embedded FPGA intellectual property and chiplet-related opportunities.
President and Chief Exec
Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
On the company’s first-q
Looking for a growth ETF for your next $1,000 investment? XIT offers long‑term performance and concentrated exposure to Canada’s top technology stocks.
NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.
The company reported total revenue of $22.1 million for the first qu
Nextpower (NASDAQ:NXT) reported a strong finish to fiscal 2026, with executives pointing to record backlog, growth in its core solar tracker business and a broader push into power plant technology as key themes for the year ahead.
Chief Executive Officer and Founder Dan Shugar said the company deli
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said
Spectral AI (NASDAQ:MDAI) said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
On the compan
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the declin
National CineMedia (NASDAQ:NCMI) reported first-quarter 2026 results that management said were in line with expectations, as the cinema advertising company faced typical seasonal weakness, advertising competition from the Winter Olympics and a one-week fiscal calendar shift.
Chief Executive Officer
Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the fi
Lumexa Imaging (NASDAQ:LMRI) reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weather-related disruptions.
Chief Executive Officer Caitlin Zulla said the company “recovered our mom
Izea Worldwide (NASDAQ:IZEA) reported lower first-quarter 2026 revenue as the influencer marketing company said it completed a strategic shift away from small and midsize business accounts and toward larger enterprise clients.
Chief Executive Officer Patrick Venetucci told investors that the compan
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.
Chief Executive Officer Cat
HireQuest (NASDAQ:HQI) reported lower first-quarter revenue following the divestiture of certain MRI Network assets, while management said demand trends improved as the quarter progressed and have become more favorable early in the second quarter.
Chief Executive Officer Rick Hermanns described the
Hyperfine (NASDAQ:HYPR) reported a sharp year-over-year increase in first-quarter revenue and reiterated its full-year 2026 outlook, as management pointed to continued adoption of its next-generation Swoop portable MRI system across hospitals, neurology offices and international markets.
President
Intellicheck Mobilisa (NASDAQ:IDN) reported higher first-quarter revenue and profitability, with management saying growth in banking and lending helped offset weaker transaction volumes in retail, automotive and title insurance amid a challenging macroeconomic backdrop.
President and CEO Bryan Lewi
GrowGeneration (NASDAQ:GRWG) reported higher first-quarter 2026 revenue and a narrower loss, with management pointing to commercial business momentum, proprietary brand growth and contributions from its storage solutions segment as key drivers.
On the company’s earnings call, Co-Founder and Chief E
Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company’s first-quarter 2026 earnings call.
Chief Executive Officer Dr. Harith R
